Fragile X syndrome
The most common inherited cause of intellectual disability and a leading single-gene cause of autism — where targeted drug trials continue despite setbacks.
Fragile X syndrome is the most common inherited cause of intellectual disability and the most common single-gene cause of autism. It is caused by a change (a CGG repeat expansion) in the FMR1 gene that switches off production of a protein (FMRP) needed for normal brain connections. Features include developmental delay and intellectual disability, autism spectrum features, anxiety, ADHD, sensory sensitivity and characteristic physical features. Care is currently supportive, and although several targeted drugs have been disappointing in trials, research continues.
At a glance
- Gene
- FMR1 (CGG repeat expansion silences FMRP)
- Significance
- Commonest inherited intellectual disability; leading single-gene autism cause
- Inheritance
- X-linked; boys usually more affected than girls
- Features
- Developmental delay, autism, anxiety, ADHD, sensory issues
- Targeted drugs
- In trials; results so far mixed (e.g. zatolmilast)
What it is
Fragile X syndrome is caused by an expansion of a repeated sequence (CGG) in the FMR1 gene on the X chromosome. When the repeat becomes large enough, the gene is switched off and the brain lacks FMRP, a protein important for the strength and regulation of connections between neurons. Because it is X-linked, boys are usually affected more than girls.
Common features include developmental delay and intellectual disability (ranging from mild to severe), autism spectrum features, marked anxiety and social shyness, ADHD, sensory sensitivities, and physical features such as a long face, prominent ears and, after puberty, large testes. Carriers of smaller 'premutation' expansions can have their own associated conditions.
Diagnosis
Diagnosis is by a specific genetic test for the FMR1 CGG repeat. Because Fragile X is inherited and has implications for the wider family (including premutation carriers), genetic counselling is an important part of care.
Treatment and the research pipeline
There is no cure, and care is currently centred on early intervention, education, speech and language and occupational therapy, and treatment of associated problems such as anxiety, ADHD and sleep. Supporting communication and managing the environment to reduce anxiety and sensory overload make a real difference.
Fragile X has been a major focus of targeted drug research, but the road has been hard: several earlier approaches (for example drugs acting on the mGluR5 or GABA-B systems) did not show benefit in trials. The most advanced recent candidate, zatolmilast (a PDE4D inhibitor), did not meet its main cognitive goal in its 2025 Phase 3 studies, although the adult study showed a signal of improved everyday functioning and language; an extension study and further analysis are ongoing. Gene-based and other targeted strategies remain in earlier-stage research.
Despite real scientific effort, no medicine yet changes the core of Fragile X. Be cautious of unproven 'treatments', and treat trial results — positive or negative — as information to discuss with your specialist.
How an educational review can help
An educational review can explain the genetic result and what it means for your child and family (including carrier implications), set out which supports have the best evidence, and put drug-trial news in honest context. It is educational and does not replace your clinician's care.
Selected sources
- Reviews of Fragile X syndrome: genetics, clinical features and management.
- Shionogi/Tetra Therapeutics. Zatolmilast (BPN14770): Phase 3 EXPERIENCE-301 and -204 results, 2025.
Last reviewed: 2026-05-22
Related treatments
Have a report you want explained?
Share your child's records and our specialists will prepare a written educational review.
Start a ReviewZatay Medical provides independent educational reviews only. Our reports are not a diagnosis, treatment, or prescription, and do not replace care from your treating physician.